// App-Quantinova.ai

Su1085 : Reduction of Fecal Calprotectin and Clinical Symptoms in the Phase 2 Study of Laquinimod for the Treatment of Active Moderate-to-Severe Crohn's Disease

Researchers

Presenter

  • William Sandborn

Principal Investigators

  • Jean-Frederic Colombel

  • Kurt Brown

  • Asi Haviv

  • Hadas Barkay

  • Anat Sakov

  • Brian G. Feagan

Medical Centers

  • UCSD Inflammatory Bowel Disease Center, University of California, San Diego, CA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

Locations

  • United States

  • Canada

  • Netherlands

Companies

  • Teva Pharmaceutical

  • Chiasma Inc.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Faecal calprotectin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • double blind/blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved